STRO-006: an ITGB6 TOP1i-ADC

SUTRO BIOPHARMA

Alice Yam
World ADC Summit, San Diego
November 5, 2025

October 2025

NASDAQ: STRO

Sutro Biopharma

- Location: South San Francisco, CA
- Founded: 2003, publicly traded since 2018
- Platform Technology: Cell-free protein synthesis, enabling non-natural amino acid incorporation and site-specific conjugation
- Evolution of the platform:
  - GMP manufacturing in pilot plant
  - Fully externalized manufacturing
  - Commercial-ready

Site-Specific Technology is Enabled by Non-Natural Amino Acid Incorporation

- Cell Free Protein Synthesis enables non-natural amino acid incorporation
- Copper-free click conjugation
  - Orthogonal chemistry
  - Rapid
  - Homogeneous
  - Extremely stable
- Expanded design space to construct optimized ADCs
  - Higher stability
  - Better PK
  - More safety



Pharmacology Attributes of “Winner” ADCs



MTD: maximum tolerated dose, HNSTD: highest non-severely toxic dose

Sutro Cell-Free Manufacturing Platform Enables Site-Selective ADCs with Superior Exposure and Design Flexibility

Surface Sites Screened on an IgG



DAR16 ADCs



Choosing <u>the right combination</u> of sites can result in optimized pharmacokinetics

- Better PK
- Less ADC Clearance
- Less Systemic Toxicity

Sutro's ADCs Display High Exposure in NHPs

Comparison of Exposure Levels in NHPs at Highest Non-Severely Toxic Dose (HNSTD) Levels in DAR Equivalents



Why does it matter?

- For ADCs, exposure drives efficacy
- Conventional ADCs display limited exposure as premature payload release causes platform toxicity
- Sutro's exatecan ADCs are positioned to be differentiated on safety and efficacy versus on-market ADCs

Exatecan/Topo1i ADCs

Tubulin inhibitor ADCs

Clinical Precedence for Higher ADC Exposure Leading to Better ORR

Payload Adjusted Dose in Clinic

Same Payload Dose



Conventional DAR4 MUC16 ADC
Site Specific DAR2 MUC16 ADC



ADC Exposures in Clinic

Higher Exposure With Site Specific ADC





Better ORR With Site Specific ADC

Site-specific ADC leads to:

- Superior PK
- > 4x improved ADC exposure
- Improved ORR

ADC exposure in NHPs correlates with clinical exposure

Garg, et al (2017) Cancer Research; Liu, et al (2021) Gynecologic Oncology; Liu, et al (2016) Annals of Oncology; PK and exposure data for expansion doses of 2.4 mg/kg and 5.2 mg/kg are shown for DMUC5754A and DMUC4064A, respectively

Pipeline of Next-Generation Single- and Dual-Payload ADCs

	PROGRAM	MODALITY/TARGET	INDICATION	DISCOVERY	PRECLINICAL	PHASE 1/1B	PHASE 2	PHASE 3/ REGISTRATIONAL	PARTNER
WHOLLY-OWNED PROGRAMS	**STRO-004**	Tissue Factor ADC	Solid Tumors						
	STRO-006	Integrin αvβ6	Solid Tumors						
	STRO-00X	PTK7 Dual-Payload ADC	Solid Tumors						
	STRO-00Y	Dual-Payload ADC	Solid Tumors						
PARTNERED PROGRAMS	**VAX-24**	24-Valent Conjugate Vaccine	Invasive Pneumococcal Disease						VAXCYTE protect humankind
	VAX-31	31-Valent Conjugate Vaccine	Invasive Pneumococcal Disease						
	Undisclosed Programs	Immunostimulatory ADCs (iADCs)	Cancers						astellas

STRO-006

Potential Best-in-Class Exatecan ADC Targeting Integrin-Beta 6

SUTRO BIOPHARMA

Integrins Function at the Interface Between Cells and the Extracellular Matrix (ECM)



- Integrins are heterodimers (α/β subunits)
- Diverse functions depending on where expressed
- Multiple conformational states; act as mechanotransducers between the cell and ECM
- Integrins link extracellular ECM proteins to intracellular cytoskeletal components
- Facilitate cellular migration and invasion

Brown, et al (2019) Cancers

Within the Integrin family, Integrin β6 (ITGB6) has a unique role in tissue homeostasis



- ITGB6 belongs to a family of integrin proteins
- ITGB6 heterodimerizes exclusively with αv
- ITGB6 (αvβ6) expression in adult tissues is associated with wound healing or tissue remodeling
- Specialized for the activation of TGFβ

Steiger, et al (2021) EJNMMI Research

ITGB6 is an important regulator of TGFβ signaling

- TGFβ is a cytokine with pleiotropic effects
- In normal tissues, helps maintain tissue homeostasis and repair
- In advanced tumors, TGFβ can drive immunosuppressive phenotype
- ITGB6 is an important activator of TGFβ
- TGFβ is stored within the ECM; local activation occurs via ITGB6-mediated binding to latent complexes, resulting in TGFβ release



Inactive latent complex **ITGB6-mediatedTGFβ release**

Brown, et al (2019) Cancers

ITGB6 is Expressed in Broad Set of Primary Solid Tumor Indications



Tumor Type	Most Common Histology on TMA	% positive
Lung cancer	NSCLC	71%
Breast Cancer	Invasive ductal carcinoma	68%
TNBC	Invasive ductal carcinoma	65%
Colon Cancer (CRC)	Colorectal adenocarcinoma	63%
Gastric Cancer	Gastric adenocarcinoma	58%
Esophageal Cancer	Squamous cell carcinoma	88%
	Adenocarcinoma	56%
Head & Neck Cancer	Squamous cell carcinoma	88%







STRO-006: Selective ITGB6-Targeting Exatecan ADC for Leading Tolerability and PK

2-3x higher drug exposure than many conventional ADCs



1 ANTIBODY

- High affinity to ITGB6 without effect on TGFβ signaling
- Fc-silent to reduce ILD risk

2 PAYLOAD

- High stable DAR (8)
- Potent anti-tumor activity with bystander effect

3 LINKER

- β-glu linker with robust *in vivo* stability to minimize premature release and enhance PK and tolerability

UPCOMING MILESTONES

IND filing planned for 2026

DAR – Drug to antibody ratio; ILD – Interstitial lung disease; IND – Investigational new drug; ITGB6 – Integrin-beta 6; PK – Pharmacokinetic; TGFβ – Transforming growth factor-beta

ITGB6: Attractive Broad Solid Tumor Target but Biologically Complex—Requires Advanced Engineering



STRO-006 binds specifically to ITGB6 and not to related integrin family members, limiting off-target toxicity

Steiger, et al (2021) EJNMMI Research

STRO-006 Binds Specifically to αvβ6 and Not Other Integrin Family Members



Avβ6-specific binding out of >6500 proteins screened in a cell-based microarray

STRO-006 is designed for strong safety and does not interfere with TGFβ signaling



ITGB6 has an important function in tissue remodeling and repair

- This function is mediated by TGFβ
- TGFβ exists in an inactive state, encompassed within the 'Latent TGFβ-LAP' complex
- Binding of the complex to αvβ6 results in release of TGFβ

STRO-006 does not inhibit ITGβ6-driven TGFβ signaling, a key pathway in tissue repair



Brown, et al (2019) Cancers

STRO-006 is Designed for Superior Selectivity, Safety and Stability

STRO-006 Exhibits Favorable Safety, PK, and Stability Profile in NHP Studies

- Well-tolerated up to 25 mg/kg (q3w x2) with no body weight loss
- No signs of neutropenia or lymphopenia
- Exhibits long half-life, low clearance & stable ADC



NHP – Non-human primate; PK – Pharmacokinetic

Single Dose of STRO-006 Drove Durable and Dose-Dependent Tumor Response in Xenograft Models

Head and Neck (ITGB6+)



Bladder (ITGB6++)



Lung (ITGB6+++)



ITGB6 – Integrin beta 6; MMAE – Monomethyl auristatin E

Anti-Tumor Activity of STRO-006 in HNSCC PDX Models at Clinically Relevant Dose Show Strong Clinical Potential





STRO-006 Elicits Potent Anti-Tumor Response with Prolonged Duration of Response in HNSCC PDX Models





Landmark response

ADC	Response (below baseline) at end of study
STRO-006	7/11 (64%)
aITGB6 DAR4 MMAE	3/11 (27%)

STRO-006 is a Next-Generation Integrin β6-Targeting TOPO1i-ADC with Best-in-Class Potential

- STRO-006 is an integrin β6-targeting Exatecan-ADC designed for enhanced stability, potency and tumor selectivity
- STRO-006 has best-in-class potential, distinguished by:
  - Improved safety – specificity of mAb targeting and β-glu linker design
  - Better targeting – high internalization rate and site-specific conjugation
  - More efficacy – through improved drug exposure and high potency/bystander exatecan
- ITGB6 targeting has broad potential across many cancers, with clinical validation in NSCLC, HNSCC, and esophageal cancers.
- Based on these promising preclinical activity, an IND is planned for 2026

DESIGNED TO DELIVER

THANK YOU

SUTRO BIOPHARMA

For partnering opportunities

Contact: Barbara Leyman, bleyman@sutrobio.com